Please login to the form below

Not currently logged in
Email:
Password:

Professor Thomas Cech joins Storm Therapeutics

He takes up a scientific advisor role at the group

Thomas CechStorm Therapeutics, a company focused on the discovery of small molecule therapies has appointed Professor Thomas Cech as its scientific advisor.

Professor Cech’s career has seen him spend decades researching into RNA biology and he became the scientific founder of Ribozyme Pharmaceuticals. He currently serves on the board of directors of Merck & Co.

Commenting on the new appointments, Keith Blundy, chief executive officer of Storm Therapeutics, said: “We are very pleased to have attracted such an internationally renowned researcher as Professor Cech to Storm.

“As a leader in the field of RNA biology, Tom’s in-depth knowledge, insight and experience will be invaluable as we look to continue building a drug discovery platform and mature into a world leading therapeutics company targeting RNA epigenetic modulation.”

His new role will see him join recent hires Professor Mark Dawson and Dr Paul Leeson to boost Storm’s pipeline.

9th February 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics